TECTONIC IDE Trial of Abbott’s Coronary IVL Device Completes Enrollment 

April 21, 2026—Abbott Vascular has completed patient enrollment in the TECTONIC coronary artery disease (CAD) intravascular lithotripsy (IVL) investigational device exemption (IDE) study of the company’s new coronary IVL system in the treatment of severe calcification in coronary arteries before stenting.

Conavi’s IVUS-OCT System for Intravascular Imaging Cleared by FDA

April 21, 2026—Conavi Medical Corp., a developer of imaging technologies to guide common minimally invasive cardiovascular procedures, announced that it has received FDA 510(k) clearance for its next-generation hybrid imaging system.

KingstronBio Announces First Implant of ProStyle M Transcatheter Mitral Valve System in Confirmatory Study

April 20, 2026—China-based KingstronBio Technology (Changshu) Co., Ltd. announced the first implantation of the company’s ProStyle M transcatheter mitral valve system in a national multicenter confirmatory clinical study to verify the device’s safety and efficacy.

Elucid Introduces Lesion Inspection Tool for Plaque-IQ Software Suite

April 20, 2026—Elucid announced the commercial availability of a new lesion inspection tool for coronary and carotid plaque analysis in its Plaque-IQ software suite.

Medtronic Completes Acquisition of CathWorks

April 20, 2026—Medtronic announced it has completed its acquisition of CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease with its fractional flow reserve (FFR) diagnostic technology.

Bayer’s Asundexian FXIa Inhibitor Demonstrates Reduction in Ischemic Stroke in OCEANIC-STROKE Study

April 17, 2026—The results from the OCEANIC-STROKE study were published by Mukul Sharma, MD, et al in The New England Journal of Medicine (NEJM; 2026;394:1467-1479).

Stereotaxis to Acquire Robocath

April 15, 2026–Stereotaxis, a St. Louis, Missouri–based company focused on robotics for endovascular intervention, announced that it has entered into a definitive agreement to acquire Robocath.

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

PROTECT H2H Directly Compares Stroke Protection Devices During TAVR 

April 12, 2026—The American College of Cardiology (ACC) announced that findings from the PROTECT H2H randomized trial were presented at the ACC.26 annual scientific session.

Innoventric’s Unica System to Treat Severe TR Granted FDA Breakthrough Device Designation

April 10, 2026—Innoventric, an Israel-based medical device company, announced that its Unica system for the treatment of severe tricuspid regurgitation (TR) has been granted FDA Breakthrough Device designation.